NICE technology appraisal guidance
Issued: June 2012
TA258

Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer

This is an extract from the guidance. The complete guidance is available at guidance.nice.org.uk/ta258

1 Guidance

1.1 Erlotinib is recommended as an option for the first-line treatment of people with locally advanced or metastatic non-small-cell lung cancer (NSCLC) if:

  • they test positive for the epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation and

  • the manufacturer provides erlotinib at the discounted price agreed under the patient access scheme (as revised in 2012).